ADC Therapeutics Extends Cash Runway into 2028, Reports Q1 Revenue Growth
Summary
ADC Therapeutics reported its first-quarter 2026 financial results, highlighting net product revenue of $20.0 million, an increase from $17.4 million in the prior year. Critically, the company announced a robust cash position of $231.0 million as of March 31, 2026, which is expected to fund operations at least into 2028. This significant extension of the cash runway provides substantial financial stability and de-risks the company's ability to advance its clinical pipeline. Upcoming catalysts include topline data from the LOTIS-5 Phase 3 trial in the second quarter of 2026, with full data for both LOTIS-5 and LOTIS-7 anticipated by year-end, which could lead to a supplemental Biologics License Application (sBLA) submission. This news is new and material, not previously disclosed in recent SEC filings.
At the time of this announcement, ADCT was trading at $4.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $487.1M. The 52-week trading range was $1.23 to $4.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.